Long-term survival after resection of sarcomatoid carcinoma of the pancreas: an updated experience

摘要: Abstract Background Sarcomatoid carcinoma of the pancreas (SCP) is a rare histologic subtype undifferentiated pancreatic carcinoma. Historically, this has been associated with worse overall prognosis than adenocarcinoma. However, clinical course and surgical outcomes SCP remain poorly characterized owing to its rarity. Methods A single-institution, prospectively maintained database was queried for patients who underwent resection final diagnosis SCP. We describe their histology, clinicopathologic features, perioperative outcomes. Survival data are highlighted, common traits long-term survivors examined. Results Over 25-year period, 7009 patents at our institution. Eight (0.11%) were diagnosed on histopathology. R0 achieved in six (75%). Four had early recurrence leading death ( 5 years), longest surviving nearly 16 years despite presence lymph node metastasis. There no deaths attributed complications. Both disease body/tail received adjuvant radiotherapy. One also gemcitabine-based chemotherapy. Conclusions rarely appreciated subset malignancy that does not necessarily portend uniformly dismal prognosis. Although some have rapid an demise, survival may be possible. Future studies needed better define cohort potential so aggressive therapies tailored appropriately patient subset.